Jesper Andreas Palshof

495 total citations
16 papers, 361 citations indexed

About

Jesper Andreas Palshof is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Jesper Andreas Palshof has authored 16 papers receiving a total of 361 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 5 papers in Surgery. Recurrent topics in Jesper Andreas Palshof's work include Cancer therapeutics and mechanisms (4 papers), Colorectal Cancer Treatments and Studies (4 papers) and Lung Cancer Research Studies (4 papers). Jesper Andreas Palshof is often cited by papers focused on Cancer therapeutics and mechanisms (4 papers), Colorectal Cancer Treatments and Studies (4 papers) and Lung Cancer Research Studies (4 papers). Jesper Andreas Palshof collaborates with scholars based in Denmark and Switzerland. Jesper Andreas Palshof's co-authors include Dorte Nielsen, Benny Vittrup Jensen, Iben Kümler, Michael Andersson, Karen‐Lise Garm Spindler, Per Pfeiffer, Finn Ole Larsen, Nils Brünner, Jan Stenvang and Birgitte Martine Viuff and has published in prestigious journals such as Scientific Reports, International Journal of Molecular Sciences and Annals of Oncology.

In The Last Decade

Jesper Andreas Palshof

15 papers receiving 357 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jesper Andreas Palshof Denmark 9 246 134 99 49 49 16 361
József Lövey Hungary 12 168 0.7× 153 1.1× 90 0.9× 59 1.2× 49 1.0× 46 406
Cristina Smolenschi France 10 232 0.9× 90 0.7× 98 1.0× 20 0.4× 84 1.7× 47 346
Erion Dobi France 14 217 0.9× 147 1.1× 74 0.7× 22 0.4× 111 2.3× 31 356
L. Hart United States 11 254 1.0× 183 1.4× 220 2.2× 22 0.4× 66 1.3× 25 518
Aurélie Ferru France 11 250 1.0× 82 0.6× 93 0.9× 42 0.9× 86 1.8× 30 439
Letizia Laera Italy 12 119 0.5× 179 1.3× 101 1.0× 51 1.0× 72 1.5× 32 329
Giuseppe Colantuoni Italy 13 317 1.3× 182 1.4× 185 1.9× 33 0.7× 86 1.8× 28 509
Eric Xueyu Chen Canada 9 187 0.8× 85 0.6× 126 1.3× 15 0.3× 93 1.9× 54 370
Paul Swanson United States 7 212 0.9× 98 0.7× 141 1.4× 38 0.8× 37 0.8× 9 334
S. Sugarman United States 9 332 1.3× 100 0.7× 101 1.0× 32 0.7× 50 1.0× 16 410

Countries citing papers authored by Jesper Andreas Palshof

Since Specialization
Citations

This map shows the geographic impact of Jesper Andreas Palshof's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jesper Andreas Palshof with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jesper Andreas Palshof more than expected).

Fields of papers citing papers by Jesper Andreas Palshof

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jesper Andreas Palshof. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jesper Andreas Palshof. The network helps show where Jesper Andreas Palshof may publish in the future.

Co-authorship network of co-authors of Jesper Andreas Palshof

This figure shows the co-authorship network connecting the top 25 collaborators of Jesper Andreas Palshof. A scholar is included among the top collaborators of Jesper Andreas Palshof based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jesper Andreas Palshof. Jesper Andreas Palshof is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Palshof, Jesper Andreas, Niels Fristrup, Niels Viggo Jensen, et al.. (2025). Nationwide Real-World Outcomes of Trial Eligible and Trial Ineligible Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab. Clinical Genitourinary Cancer. 23(6). 102450–102450.
2.
Møller, Anne Kirstine Hundahl, et al.. (2023). Combination therapy with immune check point inhibitors and acute kidney injury. Acta Oncologica. 62(2). 121–125. 2 indexed citations
3.
4.
Persson, Gitte Fredberg, et al.. (2022). Active use of electronic patient-reported outcome in kidney cancer and effect on self-reported physical function: PRORECECA study protocol. Acta Oncologica. 61(12). 1473–1476. 1 indexed citations
5.
Palshof, Jesper Andreas, Estrid Høgdall, Tim Svenstrup Poulsen, et al.. (2020). ABCG2 Protein Levels and Association to Response to First-Line Irinotecan-Based Therapy for Patients with Metastatic Colorectal Cancer. International Journal of Molecular Sciences. 21(14). 5027–5027. 8 indexed citations
6.
Kümler, Iben, Peter G. Sørensen, Jesper Andreas Palshof, et al.. (2018). Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics. Cancer Chemotherapy and Pharmacology. 83(1). 169–178. 11 indexed citations
7.
Palshof, Jesper Andreas, Finn Ole Larsen, Tim Svenstrup Poulsen, et al.. (2018). Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer. Acta Oncologica. 57(8). 1057–1062. 24 indexed citations
8.
Palshof, Jesper Andreas, Estrid Høgdall, Tim Svenstrup Poulsen, et al.. (2017). Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer. BMC Cancer. 17(1). 48–48. 17 indexed citations
9.
Palshof, Jesper Andreas, Finn Ole Larsen, Estrid Høgdall, et al.. (2017). Risk factors for brain metastases in patients with metastatic colorectal cancer. Acta Oncologica. 56(5). 639–645. 23 indexed citations
10.
Nielsen, Dorte, Jesper Andreas Palshof, Nils Brünner, Jan Stenvang, & Birgitte Martine Viuff. (2017). Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A Review. International Journal of Molecular Sciences. 18(9). 1926–1926. 49 indexed citations
11.
Spindler, Karen‐Lise Garm, et al.. (2016). Systematic review: brain metastases from colorectal cancer—Incidence and patient characteristics. BMC Cancer. 16(1). 260–260. 75 indexed citations
12.
Schou, Jakob Vasehus, Benny Vittrup Jensen, Dorte Nielsen, et al.. (2016). Prognostic mRNA expression signatures in whole blood in patients with metastatic colorectal cancer treated with 3rd line cetuximab and irinotecan. Annals of Oncology. 27. vi189–vi189. 1 indexed citations
13.
Palshof, Jesper Andreas, Finn Ole Larsen, Estrid Høgdall, et al.. (2016). Risk factors for brain metastases in patients with metastatic colorectal cancer. Annals of Oncology. 27. vi192–vi192. 3 indexed citations
14.
Palshof, Jesper Andreas, Tine Plato Hansen, Anne Katrine Duun‐Henriksen, et al.. (2016). Antibody validation and scoring guidelines for ABCG2 immunohistochemical staining in formalin-fixed paraffin-embedded colon cancer tissue. Scientific Reports. 6(1). 26997–26997. 6 indexed citations
15.
Nielsen, Dorte, Jesper Andreas Palshof, Finn Ole Larsen, Benny Vittrup Jensen, & Per Pfeiffer. (2014). A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/− targeted therapy. Cancer Treatment Reviews. 40(6). 701–715. 60 indexed citations
16.
Nielsen, Dorte, Iben Kümler, Jesper Andreas Palshof, & Michael Andersson. (2012). Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. The Breast. 22(1). 1–12. 80 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by József Lövey Breakdown of academic impact, for papers by Cristina Smolenschi Breakdown of academic impact, for papers by Erion Dobi Breakdown of academic impact, for papers by L. Hart Breakdown of academic impact, for papers by Aurélie Ferru Breakdown of academic impact, for papers by Letizia Laera Breakdown of academic impact, for papers by Giuseppe Colantuoni Breakdown of academic impact, for papers by Eric Xueyu Chen Breakdown of academic impact, for papers by Paul Swanson Breakdown of academic impact, for papers by S. Sugarman
Rankless by CCL
2026